echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Takeda's potential "first-in-class" therapy for NSCLC receives FDA priority review

    Takeda's potential "first-in-class" therapy for NSCLC receives FDA priority review

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Takeda announced that the U.


    Non-small cell lung cancer is the most common type of lung cancer.


    Mobocertinib is a potent oral small molecule tyrosine kinase inhibitor specifically designed to selectively target EGFR exon 20 insertion mutations.


    The priority review qualification is awarded based on the results of Phase 1/2 clinical trials.


    ▲Phase 1/2 clinical trial results of Mobocertinib (picture source: reference [2])

    Reference materials:

    [1] Takeda Announces US FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer.


    [w] Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.